Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response

  • Federico Innocenti

Part of the Cancer Drug Discovery and Development™ book series (CDD&D)

Table of contents

  1. Front Matter
    Pages i-xiv
  2. Genomic Experimental Approaches in Oncology

    1. Front Matter
      Pages 1-1
    2. Natalie Stickle, Neil Winegarden
      Pages 3-18
    3. Yasuhiro Kuramitsu, Kazuyuki Nakamura
      Pages 33-45
    4. Soken Tsuchiya, Yasushi Okuno, Gozoh Tsujimoto
      Pages 47-56
    5. Anders Wallqvist, Ruili Huang, David G. Covell
      Pages 57-74
  3. Pharmacogenomics of Toxicity and Response of Chemotherapy

    1. Front Matter
      Pages 90-90
    2. Sharon Marsh
      Pages 91-101
    3. Rafael Rosell, Miquel Taron, Mariacarmela Santarpia, Fernanda Salazar, Jose Luis Ramirez, Miguel Angel Molina
      Pages 231-247
    4. Joseph Ciccolini, Cédric Mercier, Gérard Milano
      Pages 249-265
    5. Kimie Sai, Hironobu Minami, Yoshiro Saito, Jun-ichi Sawada
      Pages 267-286
    6. Yong Qian, Xianglin Shi, Vincent Castranova, Nancy L. Guo
      Pages 287-298
  4. Pharmacogenomics in Clinical Drug Development in Oncology

  5. Back Matter
    Pages 371-377

About this book


The availability of new molecular approaches to the selection of drug therapy is an emerging need, as the traditional approach based on the evaluation of patient and tumor characteristics is clearly far from optimal. Many, and in most cases the majority of treated patients do not have significant benefits from the treatment while they often experience moderate to severe toxicities. In "Pharmacogenomics, Anticancer Drug Discovery, and Response," edited by Federico Innocenti, readers will find a series of chapters addressing the role of genomic information in cancer therapy and in drug development representing a unique source, as it describes experimental approaches, statistical strategies, and clinical examples of the application of genomic medicine in oncology. This book provides the most comprehensive body of knowledge on the role of genetic and genomic variation in the individualization of drug therapies in cancer patients.


DNA Drogen MicroRNAs Microarrays Oncology drug development Pharmacogenomics Single Nucleotide Polymorphism Toxicogenomics anticancer drug response genes oncology proteomic analysis tumor DNA

Editors and affiliations

  • Federico Innocenti
    • 1
  1. 1.Department of Medicine, Section of Hematology/OncologyUniversity of ChicagoChicagoUSA

Bibliographic information